2012-10-29 14:11:36 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Cell Biotech Co Ltd and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Cell Biotech Co Ltd (49960). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Cell Biotech Co Ltd investor.
Report Summary: Cell Biotech Co Ltd is an average quality company with a negative outlook. Cell Biotech Co Ltd has strong business growth and is run by efficient management. The trend in Cell Biotech Co Ltd fair value exchange rate against its closest rated-competitor, ISU abxis Co., Ltd., has been appreciating over the past 2 weeks. When compared to its closest competitor, Cell Biotech Co Ltd shows greater overvaluation and is equally likely to underperform the market.
The 3-page report breaks
down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Cell Biotech Co Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.